Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis

Bioorg Med Chem. 2020 Sep 15;28(18):115673. doi: 10.1016/j.bmc.2020.115673. Epub 2020 Jul 28.

Abstract

Transthyretin (TTR) is a ß-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. TTR also interacts with amyloid-β, playing a protective role in Alzheimer's disease. Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the critical step in TTR amyloids fibrillogenesis, and is responsible for extracellular deposition of amyloid fibrils. Small molecules, able to bind in T4 binding sites and stabilize the TTR tetramer, are interesting tools to treat and prevent systemic ATTR amyloidosis. We report here the synthesis, in vitro evaluation and three-dimensional crystallographic analyses of new monoaryl-derivatives in complex with TTR. Of the derivatives reported here, the best inhibitor of TTR fibrillogenesis, 1d, exhibits an activity similar to diflunisal.

Keywords: Fibril formation inhibitors; Monoaryl derivatives; Transthyretin; X-ray TTR-ligand complexes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Binding Sites
  • Crystallography, X-Ray
  • Humans
  • Models, Molecular
  • Molecular Conformation
  • Neuroprotective Agents / chemical synthesis*
  • Neuroprotective Agents / metabolism
  • Neuroprotective Agents / pharmacology
  • Prealbumin / chemistry*
  • Prealbumin / genetics
  • Prealbumin / metabolism
  • Propionates / chemistry*
  • Propionates / metabolism
  • Propionates / pharmacology
  • Protein Aggregates / drug effects*
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Neuroprotective Agents
  • Prealbumin
  • Propionates
  • Protein Aggregates
  • propionic acid